I recently had the great pleasure of attending the renowned Founders Longevity Forum in the health and wellness capital of the world, Singapore, along with our CEO Jasmine Smith and Partnerships Manager Elvira Khismatullina.
This international meeting was hosted by the Academy for Healthy Longevity at the National University of Singapore (NUS), the Founders Forum Group (FFG), and Longevity.Technology. It was attended by a diverse global group of academics, clinicians, business leaders, and investors, driving forward innovation and investment in longevity science and medicine.
The Academy for Healthy Longevity, led by world-class experts in the field like Andrea Maier, is transforming healthy aging through groundbreaking research, innovation, and education in Precision Geromedicine. The FFG is a global community and group of businesses who champion entrepreneurship and innovation in key verticals. Longevity.Technology, headed up by the inspirational Phil Newman, is a leading media and consumer brand driving development within the longevity space.
Establishing Validated Longevity Biomarkers
As the volume of global longevity medicine clinics and treatment modalities is growing exponentially, there is a pressing need for established and validated biomarkers of aging, particularly for the identification and evaluation of contemporary longevity interventions.
This global challenge is spearheaded by the ‘Biomarkers of Aging Consortium’, established in 2023, an international group of clinicians and academics developing, validating, and implementing key biomarkers of aging and longevity. The consortium program aims to facilitate communication, collaboration and sharing of data, tools, and information to establish a bank of standardized biomarkers of aging and longevity.
Rejuve.AI is keen to play a key global role in this initiative by utilizing a decentralized platform in collaboration with the consortium, researchers, clinics, and data enthusiasts to gather big data and drive revolutionary insights into longevity science and biomarker validation. We will participate in round three of the Biomarkers of Aging Challenge, which is tackling multimorbidity.
The Importance of Government Involvement in Longevity
A key takeaway from the forum was developing solutions to enable the safe introduction of healthy longevity medicine into modern healthcare systems and establishing longevity medicine as an independent medical sub-speciality with appropriate regulation of practice.
An impressive, revolutionary example of this is the Institute for Healthier Living, Abu Dhabi (IHLAD), with the model presented wonderfully at the meeting by CEO Nicole Sirotin. A precision lifestyle medicine organization, providing precise, predictive, and preventative data-driven longevity care and research for individuals and populations.
The Department of Health (DoH) Abu Dhabi has recently licensed the institute, making it the first specialized healthy longevity centre in the world and setting global regulatory standards of care. The DoH has recently published a white paper, Healthy Longevity Medicine Clinic Standard, which will be effective from April 2025 and serve as a benchmark for regional and global regulatory standards. The Abu Dhabi model also highlights the importance of government involvement and public-private partnerships to scale the impact and development of longevity medicine provision through collaboration.
Driving Global Standards for Longevity Medicine
At the forefront of regulatory standards in longevity medicine practice is the Healthy Longevity Medicine Society (HLMS). Established in 2022, the society aims to build a clinically credible framework and platform for longevity medicine that promotes the highest standards of interdisciplinary collaboration within the field.
Throughout the two-day forum in Singapore, it became clear the importance of the HLMS to set and promote standards, including physician guidelines, in longevity medicine to advance and maintain quality of care in this relatively new discipline.
A key vision of HLMS is to facilitate and promote a clinical research agenda to evaluate longevity diagnostics and therapeutics. At Rejuve.AI, we aim to collaborate with societies like these and contribute valuable datasets and AI-driven longevity insights through our decentralized platform.